Clinical trial NCT01947738: Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)
Official title: A Two-Part, Double-Blind, Randomized, Placebo-Controlled, Sequential, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-891 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Healthy
Subjects
Safety
Tolerability
VBY891
Maximum
Pharmacodynamic
Pharmacokinetic
Lead sponsor: Virobay Inc.
Sponsor class: INDUSTRY
Collaborators: name: LEO Pharma
First posted: 2013-09-20
Enrollment: 89
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Psoriasis is an inflammatory autoimmune disease that might be controlled by a cathepsin S inhibitor like VBY-891.

Detailed description: Refer to Brief Summary

Eligibility criteria: Inclusion Criteria:

* Male or female, 18-60 years old
* Screening body mass index between 18-32 kg/m2
* Good health, no clinically significant findings in medical history, 12-lead ECG, \& vital signs;
* Clinical lab evaluations (Chem panel \[fasted at least 8 hrs\], CBC, HbA1c \& UA in reference range for test lab (unless deemed not clinically significant);
* Negative test for drugs of abuse at Screening \& at Check-in (includes alcohol);
* Negative hepatitis, HIV \& TB screens;
* Females non-pregnant, non-lactating, \& either postmenopausal for at least 1 year, surgically sterile for at least 90 days prior to Check-in, or agree to use from the time of consent until 90 days after Study Completion an effective form of contraception. For all females, a pregnancy test result must be negative at Screening \& Check-in.
* Males will be sterile or agree to use from Check-in until 90 days following discharge an effective method of contraception.
* Able to comprehend \& willing to sign Informed Consent Form

Exclusion Criteria:

* Females pregnant or nursing, or childbearing potential but unwilling to use contraception.
* History of renal or hepatic impairment; stomach or intestinal surgery or resection, malabsorption syndrome, cholecystectomy, or gastro-intestinal dysfunction that would alter absorption \&/or excretion of orally administered drugs (appendectomy or hernia repair allowed);
* Anemia (hemoglobin \<11.5 g/dL for females; \< 13 g/dL for males) or blood donation within 8 weeks of Check-in;
* Plasma donation within 4 weeks of Check-in;
* History of alcoholism or drug addiction within 6 months to Check-in;
* Use of drugs of abuse or prescription drugs for recreational use 6 months prior to Check-in;
* Use of any tobacco-containing or nicotine-containing products 6 months prior to Check-in \& during study;
* Participation in another drug trial 30 days of Check-in (within 8 weeks if previous investigational drug has immunomodulatory effects, other than cathepsin S inhibition);
* History or clinical manifestations of metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders
* History of hypersensitivity or allergies to any drug compound
* History or presence of abnormal ECG
* Laboratory abnormality deemed clinically significant;
* Use of or inability to discontinue any prescription medications/products 14 days prior to Check-in \& during study;
* Use of certain over-the-counter, non-prescription preparations are permitted up to 3 days before first dose;
* Use of alcohol-containing, grapefruit-containing, star fruit containing foods or beverages or "energy drinks" 72 hours to Check-in \& during study;
* Poor peripheral venous access;
* Receipt of blood products 6 months to Check-in
* Subjects with history of Gilbert's Syndrome;
* Strenuous activities 48 hours to Check-in
* Illness 5 days to drug administration
* Any acute or chronic condition

Primary outcomes:
measure: Safety and Tolerability of VBY-891
timeFrame: For 7 days (single dose) or 17 days (multiple dose)
Secondary outcomes:
measure: VBY-891 Blood Levels
timeFrame: 3 days (single dose) or 10 days (multiple dose)
Other outcomes:
measure: Iip10 Accumulation and Cathepsin S Protein Level
timeFrame: 24 hours
Locations:
city: Evansville
country: United States
facility: Covance Evansville
state: Indiana
Study officials:
affiliation: Virobay Inc.
name: David B. Karpf, MD
role: STUDY_DIRECTOR
References: